XL184 (cabozantinib)

cabozantinib · Exelixis

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for XL184 (cabozantinib), covering 2017-05-25 to 2017-05-25. Get the full timeline:

Most recent: Clinical Trial Update: XL184 For Relapsed/Refractory Multiple Myeloma (MM) With Bone Disease [Phase 1]